Belsomra (Suvorexant) Cost in Mississippi: Prices, Insurance, and Savings in 2026

Suvorexant is the generic name for Belsomra, an FDA-approved oral medication in the dual orexin receptor antagonist (DORA) class, used for insomnia characterized by difficulty with sleep onset and/or sleep maintenance. It is not the same drug as lemborexant (Dayvigo) or daridorexant (Quviviq), two other DORAs sometimes confused with it because they share a mechanism. Belsomra is a Schedule IV controlled substance and is available only by prescription, in 5 mg, 10 mg, 15 mg, and 20 mg tablets.

What is established: Belsomra has no FDA-approved generic as of this writing, so it is sold only as the brand at whatever price a pharmacy sets after applying insurer contracts, rebates, or discount programs. What is not established from the source material available for this article: a verified average Mississippi cash price, a confirmed current Mississippi Medicaid coverage decision, and confirmed insurer-specific copay tiers. Those figures move often enough, and vary enough by plan and pharmacy, that a general article cannot respons­ibly state one number as "the" Mississippi price. The rest of this page separates the facts that are stable and checkable against a primary source from the facts that a patient or caregiver needs to verify locally before assuming they apply.

The one paragraph worth quoting

Belsomra (suvorexant) is FDA-approved for insomnia in adults at doses of 5 mg to 20 mg taken once nightly, per the FDA-approved prescribing information, and as of 2026 no generic version has received FDA approval, so every Mississippi pharmacy dispenses the brand product. Because no generic exists, the price a Mississippi patient pays is set by a combination of the manufacturer's list price, pharmacy benefit manager contracts, and any discount card or manufacturer coupon applied at the register, not by a single fixed number. Mississippi Medicaid coverage, private insurer tier placement, and cash-pay price at any specific pharmacy all change often enough that they should be confirmed directly with the plan or pharmacy at the time of fill rather than assumed from a past estimate.

What Belsomra costs: the honest picture

Manufacturers publish a wholesale acquisition cost (list price) for brand drugs, and pharmacies then apply discounts, rebates, and coupon programs so that almost no patient pays the list price. That general pattern holds for Belsomra as it does for most brand-only prescription drugs. This article does not have a verified, dated source for the current Merck list price or for a Mississippi-specific average cash price, so neither figure is stated here as fact. Before filling a prescription, a Mississippi patient can get an accurate, current number in about five minutes by calling two or three local pharmacies (chain and independent) and asking for the cash price with any discount card the pharmacy accepts, or by using a pharmacy price-comparison tool directly.

Merck typically provides a discount card for patients with commercial insurance and a separate assistance program for uninsured individuals meeting certain income thresholds. These offerings generally do not cover patients with government plans (Medicaid, Medicare, TRICARE, VA) and include annual spending limits and enrollment criteria subject to periodic changes. Patients should verify their current eligibility for suvorexant copay assistance, the specific discount amount available, and any annual maximum by contacting Merck directly through their official support channels or asking their prescribing physician, as program terms are adjusted regularly.

Does Mississippi Medicaid cover Belsomra?

State Medicaid preferred drug lists (PDLs) change on a regular cycle, and this article does not have a current, verifiable citation to the Mississippi Division of Medicaid's PDL to state definitively whether Belsomra is covered as of a specific date in 2026. What can be said in general terms: state Medicaid programs commonly place brand-only insomnia drugs like Belsomra behind step therapy, requiring documented failure of one or more generic agents (such as zolpidem, eszopiclone, or trazodone) before approving a non-preferred brand, and many require prior authorization even after step therapy is met. Clinical guidelines from sleep medicine and internal medicine professional societies list suvorexant among several reasonable pharmacologic options for chronic insomnia in adults, which is the kind of clinical documentation a prescriber typically cites in a prior authorization request; the exact current guideline text should be checked against the issuing society's most recent published version rather than assumed from an older summary.

If a prior authorization is denied, Mississippi Medicaid enrollees have a right to appeal through the state's Medicaid fair hearing process. Confirming the correct appeal path, required documentation, and current PDL status directly with the Mississippi Division of Medicaid is the reliable route, not a secondhand estimate.

Private insurance in Mississippi

Commercial insurers operating in Mississippi, including Blue Cross Blue Shield of Mississippi and other national carriers with Mississippi plans, maintain their own formularies and update tier placement periodically. It is common industry practice for brand-only insomnia medications to sit on a non-preferred brand tier with step-therapy or prior-authorization requirements, but this article cannot confirm a specific current tier or copay range for any named Mississippi insurer without a dated, plan-specific source. The most reliable way for a patient to find their actual out-of-pocket cost is to call the member services number on the insurance card and ask three direct questions: Is suvorexant on the formulary? What tier? What step-therapy or prior-authorization steps apply? Those answers determine real cost far more accurately than any general estimate in an article.

Compounded suvorexant: what is and is not established

Under the federal framework for pharmacy compounding (Section 503A of the Food, Drug, and Cosmetic Act), state-licensed compounding pharmacies may prepare a patient-specific formulation of a drug, including a non-standard dose or a liquid form, when a prescriber determines the commercial product is not appropriate for that patient. This is a real, federally recognized pathway, and Mississippi's Board of Pharmacy licenses and regulates compounding pharmacies operating in the state. What is not established here is a specific price for compounded suvorexant in Mississippi, or a list of which pharmacies currently offer it; those details change and should be confirmed directly with a licensed 503A pharmacy.

It is also worth stating clearly: a compounded product is not an FDA-approved generic. It has not gone through the FDA's bioequivalence review, and the clinical trial evidence supporting suvorexant's efficacy and safety was generated using the brand-name tablet, not a compounded formulation. Patients considering a compounded version should confirm the pharmacy's Mississippi Board of Pharmacy license and, because suvorexant is a Schedule IV controlled substance, its DEA registration.

Telehealth prescribing in Mississippi

Federal law (the Ryan Haight Act) requires a prescriber to conduct an initial evaluation, which can be a real-time audio-video telehealth visit, before prescribing a controlled substance like suvorexant, with follow-up visits also permitted by telehealth. Mississippi has expanded telehealth practice generally, which is relevant for patients in areas with few sleep medicine specialists. Confirm that any telehealth prescriber holds an active Mississippi medical license and that the pharmacy filling the prescription can legally dispense a Schedule IV medication to a Mississippi address; both are things a patient can and should verify before an appointment, not assume.

How suvorexant fits among insomnia treatment options on cost

Generic sedative-hypnotics such as zolpidem (Ambien) and eszopiclone (Lunesta), along with off-label low-dose trazodone, are typically the least expensive pharmacologic options for insomnia and are the agents most insurers and Medicaid programs prefer as first-line. Suvorexant and the other DORAs (lemborexant, daridorexant) are brand-only with no generic competition, which is the main structural reason they cost more. The FDA-approved label describes suvorexant's mechanism as blocking orexin receptors involved in wakefulness, distinct from the GABA-receptor mechanism of Z-drugs and benzodiazepines. Clinical trials submitted for FDA approval evaluated doses of 10 mg, 20 mg, and 40 mg (40 mg was not approved) against placebo; verification of specific effect-size numbers from that trial program should be done against the primary published trial report rather than a secondhand summary, since this article does not have a confirmed, checked citation to attach to a precise effect-size claim.

Clinicians sometimes prefer a DORA over a Z-drug for patients with a history of parasomnia (sleep-related behaviors), next-day impairment, or dependence concerns, since the mechanism differs. Whether that clinical rationale justifies the added cost for a given patient is a conversation for the prescriber and patient, not a general rule.

Evidence boundary: what this page can and cannot tell you

Established: Belsomra's FDA-approved indication, dose range, and Schedule IV status; the existence of a federal 503A compounding pathway; the Ryan Haight Act's telehealth evaluation requirement for controlled substances; the absence, as of this writing, of an FDA-approved generic suvorexant.

Plausible but requiring current local verification: Mississippi Medicaid's specific coverage decision on Belsomra, any named insurer's current tier and copay, the current Merck savings card terms, and the current average cash price at Mississippi pharmacies.

Not established here: any exact dollar figure for a Mississippi cash price, insurer copay, or compounding-pharmacy price, since no dated, plan-specific or pharmacy-specific source was available to verify these figures at the time this page was drafted.

Verification checklist: stable facts vs. facts that expire

Use this checklist to separate what you can trust as a durable fact from what you must re-check before paying for or filling a Belsomra prescription in Mississippi.

Stable, federally anchored facts (safe to rely on without re-checking monthly):

• Belsomra's FDA-approved indication and dose range (5, 10, 15, 20 mg) per the FDA label
• Suvorexant's Schedule IV controlled-substance status
• The existence of the federal 503A compounding pathway for patient-specific formulations
• The Ryan Haight Act's requirement of an initial evaluation before a controlled-substance telehealth prescription
• That no FDA-approved generic suvorexant currently exists (confirm against the FDA's approval records if this matters for a specific decision, since generic status can change)

Date-sensitive facts you must re-verify before relying on them (check within days of filling a prescription, not from an old article):

• Mississippi Medicaid's current preferred drug list status for Belsomra (call the Division of Medicaid or ask the pharmacy to run a test claim)
• Your specific commercial insurer's current formulary tier and step-therapy rule for suvorexant (call member services)
• The current Merck savings card eligibility, coupon value, and annual cap (check Merck's official program materials)
• The current cash price at your specific pharmacy, and whether a discount card lowers it (call or check in person; prices differ by pharmacy and change without notice)
• Whether a specific 503A compounding pharmacy near you currently compounds suvorexant, and at what price (call the pharmacy directly and confirm its Mississippi Board of Pharmacy license and DEA registration)
• Your telehealth prescriber's active Mississippi medical license status

Any quoted suvorexant price or benefit detail presented without an associated date, specific insurance plan name, or pharmacy reference should be considered an approximation requiring verification rather than established current information.

When to seek care instead of troubleshooting cost

Cost barriers should never lead a patient to skip evaluation of insomnia that is severe, worsening, or accompanied by other symptoms. Seek prompt medical evaluation if insomnia is accompanied by loud snoring with witnessed pauses in breathing (possible sleep apnea), new depression or suicidal thoughts, chest pain, or a sudden major change in sleep pattern with no clear cause. A prescriber can also help identify whether a lower-cost first-line agent is a reasonable substitute before pursuing a brand-only drug like Belsomra.

This article is intended for general education about Belsomra (suvorexant) cost and access considerations in Mississippi. It is not a substitute for individualized medical or pharmacy advice, and coverage, price, and program details should be confirmed directly with the relevant plan, pharmacy, or prescriber before making a treatment decision.